Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia

2.

Wang

Z-Y

,

Chen

Z

.

Acute promyelocytic leukemia: from highly fatal to highly curable

.

Blood

.

2008

;

111

(

5

):

2505

-

2515

.

3.

Grimwade

D

,

Biondi

A

,

Mozziconacci

MJ

, et al.

Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party

.

Blood

.

2000

;

96

(

4

):

1297

-

1308

.

4.

Wen

L

,

Xu

Y

,

Yao

L

, et al.

Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions

.

Haematologica

.

2019

;

104

(

5

):

e195

-

e199

.

5.

Goudreault

M

,

D’Ambrosio

LM

,

Kean

MJ

, et al.

A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein

.

Mol Cell Proteomics

.

2009

;

8

(

1

):

157

-

171

.

6.

Zhang

X

,

Sun

J

,

Yu

W

,

Jin

J

.

Current views on the genetic landscape and management of variant acute promyelocytic leukemia

.

Biomark Res

.

2021

;

9

(

1

):

33-15

.

7.

Yamamoto

Y

,

Tsuzuki

S

,

Tsuzuki

M

,

Handa

K

,

Inaguma

Y

,

Emi

N

.

BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia

.

Blood

.

2010

;

116

(

20

):

4274

-

4283

.

8.

Ross

ME

,

Mahfouz

R

,

Onciu

M

, et al.

Gene expression profiling of pediatric acute myelogenous leukemia

.

Blood

.

2004

;

104

(

12

):

3679

-

3687

.

9.

Noguera

NI

,

Catalano

G

,

Banella

C

, et al.

Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies

.

Cancers (Basel)

.

2019

;

11

(

10

):

1591-21

.

10.

Fischer

K

,

Al-Sawaf

O

,

Fink

AM

, et al.

FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia

.

Blood

.

2017

;

129

(

19

):

2702

-

2705

.

11.

Tan

Y

,

Wang

X

,

Song

H

, et al.

A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia

.

Blood

.

2021

;

137

(

11

):

1503

-

1516

.

12.

Grisolano

JL

,

Wesselschmidt

RL

,

Pelicci

PG

,

Ley

TJ

.

Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulatory sequences

.

Blood

.

1997

;

89

(

2

):

376

-

387

.

13.

Wang

L

,

Shilatifard

A

.

UTX mutations in human cancer

.

Cancer Cell

.

2019

;

35

(

2

):

168

-

176

.

14.

Gozdecka

M

,

Meduri

E

,

Mazan

M

, et al.

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs

.

Nat Genet

.

2018

;

50

(

6

):

883

-

894

.

15.

Stief

SM

,

Hanneforth

A-L

,

Weser

S

, et al.

Loss of KDM6A confers drug resistance in acute myeloid leukemia

.

Leukemia

.

2020

;

34

(

1

):

50

-

62

.

16.

Wartman

LD

,

Larson

DE

,

Xiang

Z

, et al.

Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression

.

J Clin Invest

.

2011

;

121

(

4

):

1445

-

1455

.

17.

Payton

JE

,

Grieselhuber

NR

,

Chang

L-W

, et al.

High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples

.

J Clin Invest

.

2009

;

119

(

6

):

1714

-

1726

.

18.

de Jonge

HJM

,

Valk

PJM

,

Veeger

NJGM

, et al.

High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia

.

Blood

.

2010

;

116

(

10

):

1747

-

1754

.

19.

Bailly

C

.

Cepharanthine: an update of its mode of action, pharmacological properties and medical applications

.

Phytomedicine

.

2019

;

62

:

152956

.